<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Advances in Analytical Chemistry</journal-title></journal-title-group><issn pub-type="epub">2163-1557</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/AAC.2021.113016</article-id><article-id pub-id-type="publisher-id">AAC-44753</article-id><article-categories><subj-group subj-group-type="heading"><subject>AAC20210300000_49304136.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>化学与材料</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于血红蛋白氧载体的研究进展
  Research Progress Based on Hemoglobin Oxygen Carrier
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>梦媛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>梦杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>亮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>春梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南通大学公共卫生学院，江苏 南通</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>16</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>144</fpage><lpage>152</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  由于输血需求量的不断增加及血液储备不足等问题，急需一种安全有效的血液替代品。血红蛋白氧载体(HBOCs)是一种具有运载氧气能力的红细胞替代物，它以血红蛋白为原料，通过交联、聚合、偶联等化学修饰或者将其封装在人工合成的膜制备而成。基于血红蛋白氧载体保质期长，可以大量储存，在需要的时候可立即使用，也能减少在输血过程中传播病毒的风险等优点，科学家们已经研究出了许多制备血红蛋白氧载体的方法，其中结合纳米技术、层层自组装和模板技术的合成方法不仅简单易行，而且生物材料承载能力良好。使用诸如碳酸钙或碳酸锰等模板，将模板在温和的条件下溶解，操作简单且不会对材料产生影响。这给血红蛋白氧载体的应用提供了良好的技术保障。
   Due to the increasing demand for blood transfusion and insufficient blood reserve, a safe and effective blood substitute is urgently needed.Hemoglobin oxygen carriers (HBOCs) area kind of red blood cell substitutes with the ability to carry oxygen, which are prepared from hemoglobin by chemical modification such as cross-linking, polymerization, coupling or encapsulation in synthetic membranes. Due to hemoglobin oxygen carriers have many advantages, including a long shelf life, stored in large quantities and used immediately when needed, as well as reducing the risk of virus transmission during blood transfusions, scientists have developed many methods for preparing HBOCs. Among these methods, the method that combined of nanotechnology, layered self-assembly, and templating technology are not only simple and feasbile, but also have good bearing capacity of the biomaterial. The common templates such as calcium carbonate or manganese carbonate can bedissoloved under mild conditions, which is easy to operate and will not affect the fabricated product. This provides a good technical guarantee for the application of HBOCs.
 
</p></abstract><kwd-group><kwd>血红蛋白，血液替代品，氧载体，纳米技术，模板法, Hemoglobin</kwd><kwd> Blood Substitutes</kwd><kwd> Oxygen Carriers</kwd><kwd> Nanotechnology</kwd><kwd> Template Methods</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>由于输血需求量的不断增加及血液储备不足等问题，急需一种安全有效的血液替代品。血红蛋白氧载体(HBOCs)是一种具有运载氧气能力的红细胞替代物，它以血红蛋白为原料，通过交联、聚合、偶联等化学修饰或者将其封装在人工合成的膜制备而成。基于血红蛋白氧载体保质期长，可以大量储存，在需要的时候可立即使用，也能减少在输血过程中传播病毒的风险等优点，科学家们已经研究出了许多制备血红蛋白氧载体的方法，其中结合纳米技术、层层自组装和模板技术的合成方法不仅简单易行，而且生物材料承载能力良好。使用诸如碳酸钙或碳酸锰等模板，将模板在温和的条件下溶解，操作简单且不会对材料产生影响。这给血红蛋白氧载体的应用提供了良好的技术保障。</p></sec><sec id="s2"><title>关键词</title><p>血红蛋白，血液替代品，氧载体，纳米技术，模板法</p></sec><sec id="s3"><title>Research Progress Based on Hemoglobin Oxygen Carrier<sup> </sup></title><p>Mengyuan Jiang, Mengjie Su, Liang Tian, Jing Li, Chunmei Yu<sup>*</sup></p><p>School of Public Health , Nantong University, Nantong Jiangsu</p><p><img src="//html.hanspub.org/file/8-1560246x5_hanspub.png?20210831082529081" /></p><p>Received: Jul. 25<sup>th</sup>, 2021; accepted: Aug. 9<sup>th</sup>, 2021; published: Aug. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/8-1560246x6_hanspub.png?20210831082529081" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Due to the increasing demand for blood transfusion and insufficient blood reserve, a safe and effective blood substitute is urgently needed.Hemoglobin oxygen carriers (HBOCs) area kind of red blood cell substitutes with the ability to carry oxygen, which are prepared from hemoglobin by chemical modification such as cross-linking, polymerization, coupling or encapsulation in synthetic membranes. Due to hemoglobin oxygen carriers have many advantages, including a long shelf life, stored in large quantities and used immediately when needed, as well as reducing the risk of virus transmission during blood transfusions, scientists have developed many methods for preparing HBOCs. Among these methods, the method that combined of nanotechnology, layered self-assembly, and templating technology are not only simple and feasbile, but also have good bearing capacity of the biomaterial. The common templates such as calcium carbonate or manganese carbonate can bedissoloved under mild conditions, which is easy to operate and will not affect the fabricated product. This provides a good technical guarantee for the application of HBOCs.</p><p>Keywords:Hemoglobin, Blood Substitutes, Oxygen Carriers, Nanotechnology, Template Methods</p><disp-formula id="hanspub.44753-formula34"><graphic xlink:href="//html.hanspub.org/file/8-1560246x7_hanspub.png?20210831082529081"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-1560246x8_hanspub.png?20210831082529081" /> <img src="//html.hanspub.org/file/8-1560246x9_hanspub.png?20210831082529081" /></p></sec><sec id="s5"><title>1. 引言</title><p>20世纪的军事冲突使人类对血液的需求不断上升，同时也促进了输血科学技术的进步。由于当今社会人口增长、人口老龄化，以及手术数量等问题的增加，可能会导致在接下来的十年间，输血的需求增加10%以上 [<xref ref-type="bibr" rid="hanspub.44753-ref1">1</xref>]。另一份关于献血的报告指出，很多患者由于血源紧张而取消了手术，另外，非手术用途的血液库存也严重不足。到2030年，预计每年的赤字将超过300万红细胞(RBC)单位 [<xref ref-type="bibr" rid="hanspub.44753-ref2">2</xref>]。在世界范围内，由于大量平民伤亡(如自然灾害、恐怖袭击和战争)，血液供应的短缺可能会逐年增加到超过2亿的红细胞数量。由于对血液的医疗需求很高，但收集、储存和运输资源的不足，导致发展中国家和转型期国家的情况更糟 [<xref ref-type="bibr" rid="hanspub.44753-ref3">3</xref>]。</p><p>由于资金不足等问题，收集到捐献的红细胞单位的可用性也会受到一定的影响，包括对病原体检测的需要，在冷冻条件下控制储存的需要(延长保质期至6周)，和正确输血前检测的要求(以交叉配对供体和受体) [<xref ref-type="bibr" rid="hanspub.44753-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44753-ref5">5</xref>]。此外，捐献血液对献血者存在一定的内在风险，其中包括血液反应的可能性，从轻微的过敏反应到严重的休克甚至死亡 [<xref ref-type="bibr" rid="hanspub.44753-ref6">6</xref>]。这些固有的局限性加剧了捐赠的人类红细胞单位缺乏的问题，导致血源的数量和质量都没有保证。因此，开发替代红细胞的人工氧载体迫在眉睫 [<xref ref-type="bibr" rid="hanspub.44753-ref7">7</xref>]。</p><p>由于红细胞膜含有血型抗原，因此在将这些血细胞输入患者之前需要进行分型和匹配，这也是紧急情况下延误治疗的原因。而且红细胞标准储存方法下的寿命只有42天，血制品存在传染性和免疫抑制风险，如红细胞无法消毒将不能清除肝炎病毒、艾滋病毒等潜在的感染因子。</p><p>使用血红蛋白制备红细胞代用品发展至今已有数十年的历史，其间出现了多种类型，但目前仍无法进入临床实际应用，其重要原因就是出现的各种副作用，包括血管收缩、氧化损伤等 [<xref ref-type="bibr" rid="hanspub.44753-ref8">8</xref>]。基于血红蛋白的氧载体(HBOC)是在制备中使用纯化的人、动物或重组血红蛋白(Hb)的氧载体，其具有很长的储存期限，不需要冷藏或交叉配型，能够根据需要供应充足，非常适合用于治疗偏远地区的失血性休克 [<xref ref-type="bibr" rid="hanspub.44753-ref9">9</xref>]。制备HBOC所使用的血红蛋白主要是通过溶解红细胞以释放其中的血红蛋白分子，并经过纯化、彻底灭菌和病毒灭活的方法获得的。红细胞的三个主要来源为人类红细胞、牛红细胞和重组血红蛋白。其中，人类捐献的血液量可能不足以用于血红蛋白氧载体的大规模生产，因此，没有数量限制的牛血红蛋白成为制备血红蛋白氧载体最主要的来源 [<xref ref-type="bibr" rid="hanspub.44753-ref10">10</xref>]。血红蛋白氧载体从不包含红细胞酶或红细胞膜的血红蛋白，到将改性血红蛋白与红细胞抗氧化酶结合在一起，再到更接近红细胞的含有血红蛋白、红细胞酶和人造细胞膜的氧载体，逐渐趋于成熟。</p></sec><sec id="s6"><title>2. 血红蛋白的结构和功能</title><p>血红蛋白是红细胞中具有携氧能力的蛋白质，其结构(如图1)由Max Perutz于1959年确定，人类血红蛋白是由两个亚基和两个β-珠蛋白亚基组成的64 kDa四聚体蛋白质，并折叠成紧密的四级结构。其中每个α和β-珠蛋白亚基都含有一个与血红素结合的铁血红素基团，完全饱和的血红蛋白分子最多携带四个氧分子，因为它具有很高的携氧能力和胶体渗透性，是红细胞替代物的理想选择 [<xref ref-type="bibr" rid="hanspub.44753-ref11">11</xref>]，同时因其不含有红细胞膜上的众多复合的抗原，血红蛋白还具有普遍适用性。并且血红蛋白分子结构稳定，经过严格的纯化和病毒灭活过程后仍保持活性，可以储存在正常的条件下。</p><p>虽然血红蛋白有作为血液替代品的优势，但也存在着一些必须要克服的问题。首先，因为四聚体蛋白会解离成较小的二聚体和单体，血液中的血红蛋白会被迅速清除。其次，当可分解的四聚体和二聚体与游离血红蛋白结合一氧化氮时，将诱导血管收缩和肾功能不全 [<xref ref-type="bibr" rid="hanspub.44753-ref12">12</xref>]。</p><p>图1. 血红蛋白结构</p></sec><sec id="s7"><title>3. 基于纳米技术的血红蛋白氧载体</title><p>纳米技术是指从原子和分子中制造材料的科学和技术，能将生物分子组装成纳米尺寸结构。纳米技术在医学、癌症诊断和治疗、感染治疗、分子和基因修饰等医学领域具有重要的实用价值。</p><sec id="s7_1"><title>3.1. 聚合血红蛋白(PolyHb)和共轭血红蛋白</title><p>血红蛋白含有许多位于分子表面的活性氨基，其中包括赖氨酸。Chang [<xref ref-type="bibr" rid="hanspub.44753-ref13">13</xref>] 使用双功能试剂氯化癸烷和戊二醛交联血红蛋白，将血红蛋白分子聚集成聚合血红蛋白。除了使用牛血红蛋白以外，也可以使用胎盘中的红细胞解决血红蛋白的供应问题，这些在出生后被丢弃的胎盘可以作为人类血红蛋白的来源以制备聚合血红蛋白 [<xref ref-type="bibr" rid="hanspub.44753-ref14">14</xref>]。另一种合成纳米尺寸聚合血红蛋白的血红蛋白来源是由基因工程大肠杆菌产生的重组人血红蛋白 [<xref ref-type="bibr" rid="hanspub.44753-ref15">15</xref>]。</p><p>共扼血红蛋白(Conjugated hemoglobin)又称表面修饰血红蛋白，指血红蛋白与一种由高分子惰性聚合物结合而成的共轭产物，具有良好的生物相容性并能长期停留在血液循环系统中。其主要作用是提高血红蛋白的分子量，稳定血红蛋白的四聚体结构，延长半衰期，减少游离的血红蛋白，从而减轻过敏反应和肾毒性。</p><p>在分子内交联的血红蛋白 [<xref ref-type="bibr" rid="hanspub.44753-ref16">16</xref>] 和重组血红蛋白 [<xref ref-type="bibr" rid="hanspub.44753-ref17">17</xref>] 血液替代品中，所有血红蛋白呈单一血红蛋白分子形式，可引起血管加压作用和平滑肌收缩。在另一种含有36%单血红蛋白分子的聚合血红蛋白中，使用较大体积时会观察到显著的血管活性和平滑肌收缩增强的现象。相反，使用纳米生物技术为基础的聚合血红蛋白(含单分子血红蛋白 &lt; 1%)，即使大量输入也不显示出血管加压效应 [<xref ref-type="bibr" rid="hanspub.44753-ref18">18</xref>]，这可能是由于血管壁内皮细胞的细胞间连接允许单个血红蛋白分子进入细胞间隙 [<xref ref-type="bibr" rid="hanspub.44753-ref19">19</xref>]，血红蛋白可吸收到维持平滑肌正常张力所需的一氧化氮，导致血管和其他平滑肌的收缩，尤其是食道和胃肠道的收缩最为明显。</p><p>也有学者认为，不同类型的修饰血红蛋白无法比较，因为不同的血红蛋白所涉及的化学和氧亲和力存在很大差异。因此，Chang等人 [<xref ref-type="bibr" rid="hanspub.44753-ref20">20</xref>] 使用相同的戊二醛交联方法制备了含有不同百分比未聚合血红蛋白的聚合血红蛋白分子，并对它们进行表征以确保它们都具有相同的氧亲和力。他们发现游离血红蛋白含量最低的聚合血红蛋白不会导致血管收缩或心电图改变，随着游离血红蛋白的百分比增加，心电图的等电点ST段的血管收缩和升高程度增加，ST的升高可能是由于血管收缩导致心脏供氧减少。这或许可以解释一些灵长类动物和猪在注射了一种由100%的单血红蛋白分子组成的改良血红蛋白后观察到的细微心内膜病变的现象 [<xref ref-type="bibr" rid="hanspub.44753-ref17">17</xref>]。因为重组血红蛋白能穿过细胞间连接并迅速被除去，所以可以通过交联形成聚合血红蛋白来增加循环时间 [<xref ref-type="bibr" rid="hanspub.44753-ref21">21</xref>]。</p></sec><sec id="s7_2"><title>3.2. PolyHb与抗氧化酶交联</title><p>聚合血红蛋白和共轭血红蛋白适用于几种重要的临床应用，与红细胞相比，也存在其特有的优势。然而，它们只是氧气携带者，并不具有与红细胞相同的酶活性，这影响了它们在其他重要临床应用中的使用。因此，研究者开始研究聚合血红蛋白与抗氧化酶交联 [<xref ref-type="bibr" rid="hanspub.44753-ref22">22</xref>]。由于聚合血红蛋白可以在室温下保存，并能立即投入使用，因此它们具有治疗严重失血性休克的巨大潜力。然而，血红蛋白是一种反应性分子，如果存在明显的延迟并且失血性休克严重，那么仅使用氧载体再灌注可能会产生氧自由基而导致缺血再灌注损伤 [<xref ref-type="bibr" rid="hanspub.44753-ref23">23</xref>]。</p><p>Chang等 [<xref ref-type="bibr" rid="hanspub.44753-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.44753-ref25">25</xref>] 合成了基于交联聚合血红蛋白与超氧化物歧化酶和过氧化氢酶(PolyHb-SOD-CAT，如图2)的聚合血红蛋白 [<xref ref-type="bibr" rid="hanspub.44753-ref26">26</xref>]，该分子可以在运输氧气的同时去除氧自由基以减轻缺血再灌注损伤的影响。在人体器官中，肠是持续严重失血性休克中最可能由缺血再灌注损伤的器官之一，而PolyHb-SOD-CAT与聚合血红蛋白不同，前者用于再灌注缺血大鼠肠道时不会引起氧自由基的显著增加 [<xref ref-type="bibr" rid="hanspub.44753-ref27">27</xref>]。</p><p>图2. 超氧化物歧化酶(SOD)和过氧化氢酶(CAT)的分子间交联以形成PolyHb-SOD-CAT</p><p>PolyHb-SOD-CAT应用的另一个例子是由于血栓形成或其他原因引起的动脉阻塞导致的中风、心肌梗塞以及其他病症。聚合血红蛋白和结合的血红蛋白比红细胞更容易阻塞灌注部分的血管。如果动脉阻塞和缺氧延长，单独用氧载体再灌注也可能导致缺血再灌注损伤，因此，在脑卒中大鼠模型缺血60 min后，聚合血红蛋白再灌注导致血脑屏障破坏和脑水肿显着增加。然而，PolyHb-SOD-CAT可以在提供氧气的同时不引起这些不利的变化 [<xref ref-type="bibr" rid="hanspub.44753-ref26">26</xref>]。使用多硝基化交联的血红蛋白是另一种预防缺血再灌注损伤的方法 [<xref ref-type="bibr" rid="hanspub.44753-ref28">28</xref>]。</p></sec><sec id="s7_3"><title>3.3. 聚合血红蛋白与酪氨酸酶交联</title><p>恶性肿瘤部位的微循环异常，会导致组织氧张力降低，现已尝试通过使用抑制血管生成的药物来防止血管向肿瘤生长，进一步降低血液供应，但放射疗法和化学疗法只有在更高的组织氧张力下才能更好地工作。与红细胞相比，共轭血红蛋白能更有效地渗透到肿瘤的异常微循环中去，从而为放射治疗提供更多的氧气 [<xref ref-type="bibr" rid="hanspub.44753-ref29">29</xref>]。但由于共轭血红蛋白在循环中仅停留24小时，其作用持续时间短，仅能在放疗或化疗期间起作用。</p><p>聚合血红蛋白用作化疗辅助剂，能降低大鼠生长速率，增加大鼠神经胶质瘤脑瘤模型的寿命 [<xref ref-type="bibr" rid="hanspub.44753-ref30">30</xref>]。Chang和他的同事将酪氨酸酶与血红蛋白交联，形成了一种可溶性的基于纳米生物技术的PolyHb-酪氨酸酶复合物，该复合物能提供化学疗法或放射疗法所需氧气并降低全身酪氨酸水平，他们现已证明，静脉内注射PolyHb-酪氨酸酶复合物可以延缓黑色素瘤的生长，而不会引起不良反应或使治疗动物生长发生变化 [<xref ref-type="bibr" rid="hanspub.44753-ref31">31</xref>]。静脉注射PolyHb-酪氨酸酶复合物可以与微囊化酪氨酸酶的口服给药联合以维持全身性的低酪氨酸水平 [<xref ref-type="bibr" rid="hanspub.44753-ref32">32</xref>]。</p></sec><sec id="s7_4"><title>3.4. 血红蛋白脂质囊泡</title><p>在上述红细胞替代品中，血红蛋白与血液直接接触，因此需要进行高度纯化以去除微量污染物。此外，在红细胞外，血红蛋白反应活性更强，聚合血红蛋白的循环时间也比较短，仅适用于短期应用。为了避免与血液直接接触，血红蛋白脂质囊泡具有类似红细胞膜的合成膜，通过这种方式合成的人造细胞比聚合血红蛋白更接近红细胞，并且可以包含存在于红细胞中的所有酶。另外可以通过修饰细胞的表面来增加循环时间。除血红蛋白之外，合成的交联血红蛋白或重组血红蛋白都可以包封在这些人造细胞内。</p><p>Djordjevich等人使用脂质膜脂质体制备了直径 ≥ 0.2 mm的小型脂质膜人工红细胞 [<xref ref-type="bibr" rid="hanspub.44753-ref33">33</xref>]，发现它们能比上述细胞在体内循环时间更长。聚乙二醇–脂质囊泡能够显著增加氧载体在体内的循环时间 [<xref ref-type="bibr" rid="hanspub.44753-ref34">34</xref>]，聚乙二醇脂质血红蛋白囊泡已经被用于临床前动物研究且正在进行详细的安全性和功效研究以及临床试验 [<xref ref-type="bibr" rid="hanspub.44753-ref35">35</xref>]。考虑到血红蛋白的来源短缺，该研究组研究了合成血红素与脂质囊的结合，他们还将合成血红素与重组白蛋白联系起来，形成了一种氧载体 [<xref ref-type="bibr" rid="hanspub.44753-ref36">36</xref>]。</p></sec><sec id="s7_5"><title>3.5. 可生物降解共聚物膜纳米人造红细胞</title><p>Chang等将纳米生物技术与可生物降解聚合物相结合，以减少对网状内皮系统的影响，并增加血红蛋白的载量。聚乳酸是一种生物可降解聚合物，能在体内降解为乳酸，然后转化为水和CO<sub>2</sub>。合成的人造红细胞大小为80~180 nm，膜厚度5~15 nm [<xref ref-type="bibr" rid="hanspub.44753-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.44753-ref38">38</xref>]，其中血红蛋白含量约为10.97 gm/dL，但在仅含1.2 g聚乳酸的50%悬浮液中，其血红蛋白负载量可高达15 gm/dL (正常血液中的水平)，且制备过程对血红蛋白分子没有不良影响。</p></sec></sec><sec id="s8"><title>4. 制备血红蛋白氧载体的常用技术</title><p>近年来，使用层层自组装技术结合模板技术制备血红蛋白氧载体已逐渐取代传统的包封技术。此外，基于相反电荷的聚电解质交替吸附胶体粒子制备空心胶囊的方法，在微反应器、微传感器、催化体系和药物载体等领域也都得到广泛的应用 [<xref ref-type="bibr" rid="hanspub.44753-ref39">39</xref>] [<xref ref-type="bibr" rid="hanspub.44753-ref40">40</xref>]。</p><sec id="s8_1"><title>4.1. 模板法</title><p>到目前为止，碳酸盐模板是用来吸附血红蛋白最主要的多孔材料，其中尤以碳酸钙(CaCO<sub>3</sub>)和碳酸锰(MnCO<sub>3</sub>)材料研究最为广泛 [<xref ref-type="bibr" rid="hanspub.44753-ref41">41</xref>]。碳酸盐模板之所以能得到广泛的应用，主要是由于其较强的吸附能力与可控的形态和粒径(可以通过加入形态调节剂，改变反应物初始浓度等)，并能在温和的条件下将模板溶解 [<xref ref-type="bibr" rid="hanspub.44753-ref42">42</xref>]。除广泛应用于制备红细胞替代品以外，碳酸盐模板还被应用于合成各种能作为药物载体空心微囊 [<xref ref-type="bibr" rid="hanspub.44753-ref43">43</xref>]。Baeumler等人 [<xref ref-type="bibr" rid="hanspub.44753-ref44">44</xref>] 采用血红蛋白和CaCO<sub>3</sub>共沉淀法制备Hb-CaCO<sub>3</sub>微球，用戊二醛交联Hb-CaCO<sub>3</sub>微球，最后用乙二胺四乙酸(EDTA)溶解CaCO<sub>3</sub>模板以得到纯血红蛋白微球。</p></sec><sec id="s8_2"><title>4.2. 层层自组装技术</title><p>在开发的聚合物载体的各种技术中，基于层层自组装(LbL)技术的多层微囊由于其多样的涂层材料 [<xref ref-type="bibr" rid="hanspub.44753-ref45">45</xref>]，可控制胶囊的形态、大小和功能的能力，以及在特殊刺激下的多响应性 [<xref ref-type="bibr" rid="hanspub.44753-ref46">46</xref>] [<xref ref-type="bibr" rid="hanspub.44753-ref47">47</xref>]，在红细胞类微囊的合成和其他领域具有广泛的应用 [<xref ref-type="bibr" rid="hanspub.44753-ref48">48</xref>] [<xref ref-type="bibr" rid="hanspub.44753-ref49">49</xref>]。</p><p>层层自组装技术基于静电吸附作用、配位键和氢键等分子间弱相互作用，能根据需要逐层吸附不同的材料。高长有课题组 [<xref ref-type="bibr" rid="hanspub.44753-ref50">50</xref>] 利用氢氧化钙(Ca(OH)<sub>2</sub>)作为模板，将去质子化多环芳烃和戊二醛通过共价键组装到Ca(OH)<sub>2</sub>颗粒上，接着在盐酸溶液(pH = 3)中缓慢地除去Ca(OH)<sub>2</sub>的模板。获得人工红细胞胶囊后，将它们进一步包裹3层血红蛋白/戊二醛。李峻柏研究组 [<xref ref-type="bibr" rid="hanspub.44753-ref51">51</xref>] 采用层层自组装技术，将多孔球形CaCO<sub>3</sub>作为模板，通过戊二醛联在模板表面组装血红蛋白，溶解模板后得到高载量的血红蛋白微球。他们还使用MnCO<sub>3</sub>模板，通过层层自组装技术将血红蛋白和二醛肝素沉积在MnCO<sub>3</sub>模板表面，利用EDTA溶解模板得到空心微囊 [<xref ref-type="bibr" rid="hanspub.44753-ref52">52</xref>]。</p><p>通过层层自组装技术合成的微囊的氧交换能力主要取决于血红蛋白的数量及活性，所以可以通过改变血红蛋白层的数目，调节组装血红蛋白促进氧交换的容量和速率。层层自组装技术可以精确控制胶囊的形态、大小和功能，使其成为红细胞类微囊的设计和制备的有力工具。</p></sec></sec><sec id="s9"><title>5. 结束语</title><p>目前已经有很多可行的方法来修饰血红蛋白以制备改良的血红蛋白氧载体。由于我们的最终目标是在适当的临床情况下使用血红蛋白氧载体，但血红蛋白氧载体想要作为一种能完全取代输血的手段还要进行进一步的研究。根据目前的研究现状，它更适合于紧急情况下的输血，辅助心血管和血管的缺氧性疾病以及肿瘤的放疗和化疗。血红蛋白氧载体的研究对于解决全球供血不足和控制某些疾病的传播具有非常重要的意义，越来越多的科学研究人员投身到该领域进行研究。我们有理由相信，在不久的将来，血红蛋白氧载体的研究必定会有新的进展与突破，并最终应用于临床。</p></sec><sec id="s10"><title>文章引用</title><p>姜梦媛,苏梦杰,田 亮,李 静,于春梅. 基于血红蛋白氧载体的研究进展Research Progress Based on Hemoglobin Oxygen Carrier[J]. 分析化学进展, 2021, 11(03): 144-152. https://doi.org/10.12677/AAC.2021.113016</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44753-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Williamson, L.M. and Devine, D.V. (2013) Challenges in the Management of the Blood Supply. Lancet, 381, 1866-1875. https://doi.org/10.1016/S0140-6736(13)60631-5</mixed-citation></ref><ref id="hanspub.44753-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Greinacher, A., Fendrich, K. and Hoffmann, W. (2010) Demographic Changes: The Impact for Safe Blood Supply. Special Issue: XXXIst International Congress of the ISBT, 5, 239-243.  
https://doi.org/10.1111/j.1751-2824.2010.01377.x</mixed-citation></ref><ref id="hanspub.44753-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Aggarwal, S. and Sharma, V. (2012) Attitudes and Problems Related to Voluntary Blood Donation in India: A Short Communication. Annals of Tropical Medicine and Public Health, 5, 50-52.</mixed-citation></ref><ref id="hanspub.44753-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Moderypawlowski, C. L., Tian, L.L. and Pan, V. (2013) Synthetic Approaches to RBC Mimicry and Oxygen Carrier Systems. Biomacromolecules, 14, 939-948. https://doi.org/10.1021/bm400074t</mixed-citation></ref><ref id="hanspub.44753-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.M.S. (2012) From Artificial Red Blood Cells, Oxygen Carriers, and Oxygen Therapeutics to Artificial Cells, Nanomedicine, and Beyond. Artificial Cells, Blood Substitutes, and Biotechnology, 40, 197-199. 
https://doi.org/10.3109/10731199.2012.662408</mixed-citation></ref><ref id="hanspub.44753-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Napolitano, L.M. (2009) Hemoglobin-Based Oxygen Carriers: First, Second or Third Generation? Human or Bovine? Where Are We Now. Critical Care Clinics, 25, 279-301. https://doi.org/10.1016/j.ccc.2009.01.003</mixed-citation></ref><ref id="hanspub.44753-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Habler, O., Pape, A. and Meier, J. (2005) Artificial Oxygen Carriers as an Alternative to Red Blood Cell Transfusion. Der Anaesthesist, 54, 741-754. https://doi.org/10.1007/s00101-005-0893-3</mixed-citation></ref><ref id="hanspub.44753-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">杨懿铭, 王永彬, 范华骅. 抗氧化酶交联的多聚血红蛋白的制备及其自氧化稳定性研究[J]. 临床输血与检验, 2009, 11(3): 199-203.</mixed-citation></ref><ref id="hanspub.44753-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Elmer, J., Alam, H.B. and Wilcox, S.R. (2012) Hemoglobin-Based Oxygen Carriers for Hemorrhagic Shock. Resuscitation, 83, 285-292. https://doi.org/10.1016/j.resuscitation.2011.09.020</mixed-citation></ref><ref id="hanspub.44753-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">万英, 周剑涛. 血红蛋白氧载体研究进展[J]. 中国生化药物杂志, 2004(3): 178-180.</mixed-citation></ref><ref id="hanspub.44753-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Tsai, A.G., Cabrales, P. and Intaglietta, M. (2004) Oxygen-Carrying Blood Substitutes: A Microvascular Perspective. Expert Opinion on Biological Therapy, 4, 1147-1157. https://doi.org/10.1517/14712598.4.7.1147</mixed-citation></ref><ref id="hanspub.44753-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Schechter, A.N. and Gladwin, M.T. (2003) Hemoglobin and the Paracrine and Endocrine Functions of Nitric Oxide. New England Journal of Medicine, 348, 1483-1485. https://doi.org/10.1056/NEJMcibr023045</mixed-citation></ref><ref id="hanspub.44753-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.M.S. (1971) Stabilisation of Enzymes by Microencapsulation with a Concentrated Protein Solution or by Microencapsulation Followed by Cross-Linking with Glutaraldehyde. Biochemical and Biophysical Research Communications, 44, 1531-1536. https://doi.org/10.1016/S0006-291X(71)80260-7</mixed-citation></ref><ref id="hanspub.44753-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Li, T., Yu, R. and Zhang, H.H. (2006) A Method for Purification and Viral Inactivation of Human Placenta Hemoglobin. Artificial Cells Blood Substitutes and Immobilization Biotechnology, 34, 175-188.  
https://doi.org/10.1080/10731190600580231</mixed-citation></ref><ref id="hanspub.44753-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Freytag, J.W. and Templeton, D. (1997) OptroTM (Recombinant Human Hemoglobin): A Therapeutic for the Delivery of Oxygen and the Restoration of Blood Volume in the Treatment of Acute Blood Loss in Trauma and Surgery, in Red Cell Substitutes; Basic Principles and Clinical Application. Marcel Dekker, 325-334.</mixed-citation></ref><ref id="hanspub.44753-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Nelson, D.J. (1998) Blood and Hem AssistTM (DCLHb): Potentially a Complementary Therapeutic Team, in Blood Substitutes: Principles, Methods, Products and Clinical Trials. Basel, Karger, 39-57.</mixed-citation></ref><ref id="hanspub.44753-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Burhop, K., Gordon, D. and Estep, T. (2004) Review of Hemoglobin-Induced Myocardial Lesions. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, 32, 353-374.</mixed-citation></ref><ref id="hanspub.44753-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Shie, J.W., Yogeswaran, U. and Chen, S.M. (2009) Haemoglobin Immobilized on Nafion Modified Multi-Walled Carbon Nanotubes for O2, H2O2 and CCl3COOH Sensors. Talanta, 78, 896-902.  
https://doi.org/10.1016/j.talanta.2008.12.063</mixed-citation></ref><ref id="hanspub.44753-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.M.S. (1997) Blood Substitutes: Principles, Methods, Products and Clinical Trials. Basel, Karger, 62-67.</mixed-citation></ref><ref id="hanspub.44753-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yu, B., Liu, Z. and Chang, T.M.S. (2009) Polyhemoglobin with Different Percentage of Tetrameric Hemoglobin and Effects on Vasoactivity and Electrocardiogram. Artificial Cells, Blood Substitutes, and Biotechnology, 34, 159-173. 
https://doi.org/10.1080/10731190600580223</mixed-citation></ref><ref id="hanspub.44753-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Matheson, B., Kwansa, H.E. and Bucci, E. (2002) Vascular Response to Infusions of a Nonextravasating Hemoglobin Polymer. Journal of Applied Physiology, 93, 1479-1486. https://doi.org/10.1152/japplphysiol.00191.2002</mixed-citation></ref><ref id="hanspub.44753-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.M.S. (2003) Future Generations of Red Blood Cell Substitutes. Journal of Internal Medicine, 253, 527-535. 
https://doi.org/10.1046/j.1365-2796.2003.01151.x</mixed-citation></ref><ref id="hanspub.44753-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Alayash, A.I. (2004) Oxygen Therapeutics: Can We Tame Haemoglobin. Nature Reviews Drug Discovery, 3, 152-159. 
https://doi.org/10.1038/nrd1307</mixed-citation></ref><ref id="hanspub.44753-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">D’Agnillo, F. and Chang, T.M.S. (1998) Polyhemoglobin-Superoxide Dismutase-Catalase as a Blood Substitute with Antioxidant Properties. Nature Biotechnology, 16, 667-671. https://doi.org/10.1038/nbt0798-667</mixed-citation></ref><ref id="hanspub.44753-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Powanda, D. and Chang, T.M.S. (2002) Cross-Linked Poly Hb superoxide Dismutase-Catalase Supplies Oxygen without Causing Blood Brain Barrier Disruption or Brain Edema in a Rat Model of Transient Global Brain Ischemia-Reperfusion. Artificial Cells, Blood Substitutes, and Biotechnology, 30, 25-42.  
https://doi.org/10.1081/BIO-120002725</mixed-citation></ref><ref id="hanspub.44753-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.M.S. (2004) Artificial Cell Bioencapsulation in Macro, Micro, Nano, and Molecular Dimensions: Keynote Lecture. Artificial Cells, Blood Substitutes, and Biotechnology, 32, 1-23. https://doi.org/10.1081/BIO-120028665</mixed-citation></ref><ref id="hanspub.44753-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Abuchowski, A. (2016) PEGylated Bovine Carboxyhemoglobin (Sanguinate): Results of Clinical Safety Testing and Use in Patients. In: Elwell, C.E., Leung, T.S., Harrison, D.K., Eds., Oxygen Transport to Tissue XXXVII. Advances in Experimental Medicine and Biology, Springer, New York. https://doi.org/10.1007/978-1-4939-3023-4_58</mixed-citation></ref><ref id="hanspub.44753-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Buehler, P.W., Mehendale, S. and Wang, H. (2000) Resuscitative Effects of Polynitroxylated Alphaalpha-Cross-Linked Hemoglobin Following Severe Hemorrhage in the Rat. Free Radical Biology and Medicine, 29, 764-774.  
https://doi.org/10.1016/S0891-5849(00)00383-X</mixed-citation></ref><ref id="hanspub.44753-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Cabrales, P. (2013) Examining and Mitigating Acellular Hemoglobin Vasoactivity. Antioxidants &amp; Redox Signaling, 18, 2329-2341. https://doi.org/10.1089/ars.2012.4922</mixed-citation></ref><ref id="hanspub.44753-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Pearce, L.B. (2006) HBOC-201 (Hb Glutamer-250 (Bovine), Hemopure): Clinical Studies, In: Winslow, R.M., Ed., Blood Substitutes, Academic Press, Cambridge, 437-450. https://doi.org/10.1016/B978-012759760-7/50047-0</mixed-citation></ref><ref id="hanspub.44753-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Yu, B.L., Swi, C. and Ming, T. (2004) In Vitro and in Vivo Effects of Polyhaemoglobin-Tyrosinase on Murine B16F10 melanoma. Melanoma Research, 14, 197-202. https://doi.org/10.1097/01.cmr.0000131013.71638.c0</mixed-citation></ref><ref id="hanspub.44753-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Yu, B.L. and Chang, T.M.S. (2004) Effects of Combined Oral Administration and Intravenous Injection on Maintaining Decreased Systemic Tyrosine Levels in Rats. Artificial Cells, Blood Substitutes, and Biotechnology, 32, 129-148. 
https://doi.org/10.1081/BIO-120028673</mixed-citation></ref><ref id="hanspub.44753-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Djordjevich, L. and Miller, I.F. (1980) Synthetic Erythrocytes from Lipid Encapsulated Hemoglobin. Experimental Hematology, 8, 584-592.</mixed-citation></ref><ref id="hanspub.44753-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Phillips, W.T., Klipper, R.W., Awasthi, V.D., et al. (1999) Polyethylene Glycol-Modified Liposome-Encapsulated Hemoglobin: a Long Circulating Red Cell Substitute. Journal of Pharmacology and Experimental Therapeutics, 288, 665-670.</mixed-citation></ref><ref id="hanspub.44753-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Simoni, J. (2005) Endothelial Cell Response to Hemoglobin Based Oxygen Carriers. Is the Attenuation of Pathological Reactions Possible. Keio Journal of Medicine, 52, 30-31.</mixed-citation></ref><ref id="hanspub.44753-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Tsuchida, E., Komatsu, T. and Yanagimoto, T. (2010) Preservation Stability and in Vivo Administration of Albumin-Heme Hybrid Solution as an Entirely Synthetic O2-Carrier. Polymers for Advanced Technologies, 13, 845-850.  
https://doi.org/10.1002/pat.240</mixed-citation></ref><ref id="hanspub.44753-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Yu, W.P. and Chang, T.M. (1996) Submicron Polymer Membrane Hemoglobin Nanocapsules as Potential Blood Substitutes: Preparation and Characterization. Artificial Cells, Blood Substitutes, and Biotechnology, 24, 169-183.  
https://doi.org/10.3109/10731199609117433</mixed-citation></ref><ref id="hanspub.44753-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.M.S., Powanda, D. and Yu, W. P. (2003) Analysis of Polyethylene-Glycol-Polylactide Nano-Dimension Artificial Red Blood Cells in Maintaining Systemic Hemoglobin Levels and Prevention of Methemoglobin Formation. Artificial Cells, Blood Substitutes, and Biotechnology, 31, 231-248. https://doi.org/10.1081/BIO-120023155</mixed-citation></ref><ref id="hanspub.44753-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Xu, G. R., Wang, S. H., Zhao, H. L., Wu, S. B., Xu, J. M., Li, L. and Liu, X.Y. (2015) Layer-by-Layer (LBL) Assembly Technology as Promising Strategy for Tailoring Pressure-Driven Desalination Membranes. Journal of Membrane Science, 493, 428-443. https://doi.org/10.1016/j.memsci.2015.06.038</mixed-citation></ref><ref id="hanspub.44753-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Cuomo, F., Lopez, F. and Ceglie, A. (2014) Templated Globules—Applications and Perspectives. Advances in Colloid and Interface Science, 205, 124-133. https://doi.org/10.1016/j.cis.2013.08.003</mixed-citation></ref><ref id="hanspub.44753-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Xiong, Y., Liu, Z.Z., Georgieva, R., Smuda, K., Steffen, A., Sendeski, M., Voigt, A., Patzak, A. and Bäumler, H. (2013) Nonvasoconstrictive Hemoglobin Particles as Oxygen Carriers. ACS Publications, 7, 7454-7461. 
https://doi.org/10.1021/nn402073n</mixed-citation></ref><ref id="hanspub.44753-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Wang, L.L., Yu, W.L., Gao, D.W., You, G.X., Li, P.L., Zhang, S., Zhang, J., Hu, T., Zhao, L. and Zhou, H. (2017) A PEGylated Bovine Hemoglobin as a Potent Hemoglobin-Based Oxygen Carrier. Biotechnology Progress, 33, 252-260. https://doi.org/10.1002/btpr.2380</mixed-citation></ref><ref id="hanspub.44753-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Li, H., Jia, Y. and Feng, X. (2017) Facile Fabrication of Robust Polydopamine Microcapsules for Insulin Delivery. Journal of Colloid and Interface Science, 487, 12-19. https://doi.org/10.1016/j.jcis.2016.10.012</mixed-citation></ref><ref id="hanspub.44753-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Xiong, Y., Steffen, A., Andreas, K., Mueller, S., Sternberg, N., Georgieva, R. and Baeumler, H. (2012) Hemoglobin-Based Oxygen Carrier Microparticles: Synthesis, Properties, and in Vitro and in Vivo Investigations. Biomacromolecules, 13, 3292-3300. https://doi.org/10.1021/bm301085x</mixed-citation></ref><ref id="hanspub.44753-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Rydzek, G., Ji, Q., Li, M., Schaaf, P., Hill, J.P., Boulmedais, F. and Ariga, K. (2015) Electrochemical Nanoarchitectonics and Layer-by-Layer Assembly: From Basics to Future. Nano Today, 10, 138-167. 
https://doi.org/10.1016/j.nantod.2015.02.008</mixed-citation></ref><ref id="hanspub.44753-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Szarpak, A., Cui, D. and Dubreuil, F. (2010) Designing Hyaluronic Acid-Based Layer-by-Layer Capsules as a Carrier for Intracellular Drug Delivery. Biomacromolecules, 11, 713-720. https://doi.org/10.1021/bm9012937</mixed-citation></ref><ref id="hanspub.44753-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Tong, W., Gao, C. and Möhwald, H. (2006) Single Polyelectrolyte Microcapsules Fabricated by Glutaraldehyde-Mediated Covalent Layer-by-Layer Assembly. Macromolecular Rapid Communications, 27, 2078-2083.  
https://doi.org/10.1002/marc.200600533</mixed-citation></ref><ref id="hanspub.44753-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Ma, Y., Dong, W.F. and Hempenius, M.A. (2006) Redox-Controlled Molecular Permeability of Composite-Wall Microcapsules. Nature Materials, 5, 724-729. https://doi.org/10.1038/nmat1716</mixed-citation></ref><ref id="hanspub.44753-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Kurapati, R. and Raichur, A.M. (2013) Near-Infrared Light-Responsive Graphene Oxide Composite Multilayer Capsules: A Novel Route for Remote Controlled Drug Delivery. Chemical Communications, 49, 734-736. 
https://doi.org/10.1039/C2CC38417E</mixed-citation></ref><ref id="hanspub.44753-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">She, S.P., Li, Q.Q., Shan, B.W., Tong, W.J. and Gao, C.Y. (2013) Fabrication of Red-Blood-Cell-Like Polyelectrolyte Microcapsules and Their Deformation and Recovery Behavior through a Microcapillary. Advanced Materials, 25, 5814-5818. https://doi.org/10.1002/adma.201302875</mixed-citation></ref><ref id="hanspub.44753-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Duan, L., Yan, X., Wang, A., Jia, Y. and Li, J. (2012) Highly Loaded Hemoglobin Spheres as Promising Artificial Oxygen Carriers. ACS Nano, 6, 6897-6904. https://doi.org/10.1021/nn301735u</mixed-citation></ref><ref id="hanspub.44753-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Jia, Y., Cui, Y., Fei, J.B., Du, M.C., Dai, L.L., Li, J.B. and Yang, Y. (2012) Construction and Evaluation of Hemoglobin-Based Capsules as Blood Substitutes. Advanced Functional Materials, 22, 1446-1453. 
https://doi.org/10.1002/adfm.201102737..</mixed-citation></ref></ref-list></back></article>